GlassScriptPhysician profile
David M Way
NPI 1316941669
$2,914.72
in general payments reported to CMS, 2019-2025
19 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $415 · 2021: $184 · 2022: $479 · 2023: $755 · 2024: $462 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $672.36 | 2020-2025 | Total30, Clareon, Precision 1 |
| Coopervision INC. | $588.86 | 2020-2025 | Myday Contact Lens, Cvi Contact Lens |
| Bausch & Lomb Americas INC. | $238.89 | 2022-2024 | Infuse, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $234.08 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $197.44 | 2019-2022 | |
| Abbott Laboratories | $161.79 | 2023 | Octrode |
| Shire North American Group INC | $145.92 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $123.88 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $100.72 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $90.43 | 2022-2025 | Tyrvaya |
| Notal Vision, INC. | $87.12 | 2022 | |
| Glaukos Corporation | $71.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $47.17 | 2019-2020 | |
| Biotissue Holdings INC. | $45.70 | 2019-2021 | |
| Synergeyes, INC. | $28.09 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $26.63 | 2024 | Oxervate |
| Harrow Eye, LLC | $21.10 | 2024 | Vevye |
| Optos, INC. | $21.00 | 2020 | |
| Visioneering Technologies, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Way listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.